19.5% claimed, 15.1% delivered; margin recovery path credible but risky
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Called 19.5% growth; delivered 15.1%. Margin miss vs. FY27 guidance already apparent in Q1. Transparent on one-time costs but hits guidance hard.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue growth of 15.1% YoY is solid, but falls short of management's 19.5% opening claim. EBITDA margin compression to 10.1% from 13.1% year-ago—and well below 13.5-14% full-year guidance—is the critical miss. Management blames ₹6.3 Cr prior-period wage settlement, kiln under-absorption, and project pricing lag (₹4.35 Cr total claimed one-time). Recovery to 13.5-14% margins is credible if commodities stabilize and project contracts convert in Q3, but dependent on execution risk.
₹486 Cr
Revenue · +15.1% YoY₹45.3 Cr
Reported PAT · −3.7% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Revenues grew 19.5% year-on-year during quarter
OVERSTATEDDelivered result: 15.1% YoY growth (₹486 Cr vs ₹422 Cr prior-year equivalent)
EBITDA margins at 13.5-14% full-year guidance
MISSQ1 EBITDA margin 10.1% vs 13.1% prior year; one-time impact claimed 4.35%
Strong operating leverage from revenue growth
MISSPAT declined 3.7% YoY despite 15.1% revenue growth; no leverage evident
One-time costs (4.35%) will not recur beyond Q2
PartialWage settlement ₹6.3 Cr is prior-period only; kiln under-absorption transient; project lag persists Q2
Volume-driven growth in core segments
METSanitaryware: 10% volume + 2% price + 2% mix = 14%; Faucetware: 18% volume + 4% price + 3% mix = 25%
Earnings quality
What changed since the last call
EBITDA margin guidance credibility
DowngradeQ1 10.1% vs 13.5-14% full-year guide; 3pp gap. Revised expectations for H2 now hinge on commodity price stability and project pricing, both uncertain.
Revenue growth framing
DowngradeOpened call with 19.5% YoY; delivered 15.1%. Gap suggests preliminary vs. restated figures or accounting presentation underestimated drag from discount reclassification (2.5% revenue reduction).
Wage cost structure
DowngradeNew union settlement 15-20% hike to base wages; ₹18.3 Cr full-year impact (₹1 Cr/month run-rate post-Nov). Structural headwind vs. prior guidance assumption.
Greenfield sanitaryware expansion
Neutral₹130-150 Cr capex deferred mid-2025 remains on hold; decision by end-FY27 based on demand trajectory. 61% current utilization (hampered by single-kiln ops Q1) gives capacity buffer.
The Q&A
Analysts pressed hard on volume breakup, Senator/Polipluz metrics, and margin recovery path. Management deflected on new-brand specifics ("young initiatives, difficult to break out"), but provided granular one-time cost breakdown. Brass price escalation (₹665→₹900 Dec-Jul) prompted follow-up on further hikes; management cautious but not dismissive. Gross margin compression (46% vs 50%+) flagged; CFO expects recovery to 51% by Q3 if commodity holds. Tone: honest but defensive on credibility.
Volume growth breakup — Praveen Sahay, PL Capital
AnsweredSanitaryware: 10% volume + 2% price (May impact) + 2% mix = 14%. Faucetware: 18% volume + 4% price + 3% mix = 25%. Volume momentum continuing month-on-month.
Senator/Polipluz targets — Praveen Sahay, PL Capital
DodgedThese are new initiatives in build-up phase. Difficult to give breakout metrics quarter-on-quarter. Overall projections unchanged; focus on longer-term rather than quarterly performance.
One-time wage settlement — Varun Julasaria, 360 ONE Capital
AnsweredUnion wage agreement settled May 2026, covering Sep '25–Mar '26 retroactively. ₹6.3 Cr prior-period + ₹3 Cr current = ₹9.3 Cr Q1. Full-year wage cost impact ₹18.3 Cr (15-20% base wage hike). Run-rate ~₹1 Cr/month.
Faucetware expansion needs — Varun Julasaria, 360 ONE Capital
AnsweredQ4 expansion already in progress; cannot prepone before that. Can exceed 100% utilization via outsourcing. Brass escalation noted; if breaches ₹950, further hikes likely. Current pricing protects up to ₹900.
Margin recovery path — Rahul Majethia, Stratton Oakmont Capital
AnsweredOne-time impact 4.35%: wage settlement ₹6.3 Cr (1.3%), single-kiln under-absorption ₹3.7 Cr (0.75%), project foreclosure ₹4 Cr (0.8%), delayed price effect 1.5%. Without these, would be ~14.5%. FY27 target 13.5-14% intact; recovery from Q3 as projects convert.
Greenfield expansion revival — Rahul Majethia, Stratton Oakmont Capital
AnsweredPositive demand signal. Q1 was one-off (61% utilization due to geopolitics + single kiln); June onwards at 80% utilization both plants. Decision by year-end FY27 based on demand trajectory. Project takes 18 months from start.
Gross margin trajectory — Varun Julasaria, 360 ONE Capital
AnsweredQ1 is aberration due to Faucetware brass lag. Q3 onwards should recover to 51% historical levels if brass and gas prices hold. Retail pricing now in effect July onwards; project pricing from Q3.
Guidance
FY27 18-20% revenue growth
MediumMaintained from prior guidance. Q1 actual 15.1% YoY below claim; implies H2 must sustain 18-22% to hit 18-20% full-year. Dependent on retail and project demand hold.
FY27 13.5-14% EBITDA margin
MediumQ1 miss (10.1%) but management attributes to one-time costs (4.35%). Projects margin recovery Q3+ as pricing converts, commodities stabilize. Risk: if wages/brass stay elevated, recovery delayed or incomplete.
FY27 ₹43 Cr capex investment
HighFaucetware brownfield expansion, manufacturing efficiencies, digital initiatives. Capacity addition Q4 FY27; 18-month lead time suggests greenfield (if approved end-FY27) starts FY28.
Risks the call surfaced
Commodity price inflation
HighBrass prices ₹665 (Dec)→₹900 (Jul). Further escalation to ₹950-₹1000 expected. Gross margin compressed to 46% vs. 50%+ historical. Management can pass through via price hikes, but 2-3 month lag on retail, 1+ quarter on projects.
Margin recovery execution
HighManagement claims one-time impact of 4.35%; EBITDA would be 14.5% ex-these. Recovery to 13.5-14% FY27 guidance hinges on (a) project contracts converting to new pricing by Q3, (b) commodity prices holding, (c) wage cost absorption. If any slip, full-year margin target at risk.
Capacity constraints (Faucetware)
MediumFaucetware utilization 96%; single kiln ops Q1 reduced production 30-35%. Brownfield expansion planned Q4 FY27 completion; 18-month lag if greenfield approved end-FY27. If demand acceleration occurs before capacity addition, growth may be capped or outsourcing costs rise.
Management continuity (Senator/Polipluz)
MediumMr. Baliga (CEO of new initiatives) resigning due to personal reasons; exiting Sep 30. Responsibilities handed to existing national head. Both brands still in build-up phase; continuity risk if transition mismanaged.
Morbi supply chain dependency
MediumReduced dependence via SKU internalization, but outsourcing partners in Morbi cluster still supply ~50% of production (split varies by segment). Q1 faced challenges; mitigated through internalization. Future disruptions (craft unrest, logistics, utilities) pose supply risk.
Management
Score 7/10. Transparent on one-time costs (granular breakdown of ₹6.3 Cr wage, ₹3.7 Cr kiln, ₹4 Cr project closure impacts). Deflects on Senator/Polipluz specifics (young initiatives, no quarterly breakdown). Candid on commodity price escalation risk and pricing lag. Honest about margin miss vs. guidance. Track record: Q1 margin (10.1%) vs. prior year (13.1%) shows 300 bps decline. Revenue growth claim (19.5%) vs. delivered (15.1%) is 440 bps overstatement. Volume growth (10-18% segments) delivered; pricing power demonstrated (May hikes absorbed). On-time DMS launch and SKU internalization show operational discipline.
1 · Jul 2026 onwards
Retail pricing hike (May 2026, 12-16%) now flowing through; margin uplift expected
2 · Q3 FY27 (Oct-Dec 2026)
Project contracts convert to revised pricing; ~1.5% margin recovery from deferred price pass
3 · Q4 FY27 (Jan-Mar 2027)
Faucetware brownfield capex (₹43 Cr FY27) expansion capacity comes live; eases 96% utilization
Recovery to 13.5-14% margins is credible if commodities stabilize and project contracts convert in Q3, but dependent on execution risk.
Growth Momentum Tested Against Input Costs
With FY27 guidance of 18-20% revenue growth and new brands ramping, CERA enters Q1 on a bullish footing—but margin pressure and a recent CBO departure will be on the Street's radar.
What to Expect: Growth Momentum vs. the Margin Squeeze
~₹633 Cr
In line with FY27 18–20% growth guidance; Q4 FY26 was ₹643.8 Cr
13–14%
Q4 contracted to 15.2%; recovery depends on commodity cost reprieve
7–8% (sanitaryware)
Faucetware growth guided at 10–12%; new brands scaling
~₹53.1
Analyst consensus for Q1 FY27; dependent on margin delivery
A strong quarter: Revenue at or above ₹640 Cr with EBITDA margins stabilizing at 14% or better signals that the company is absorbing input costs and executing on the 18–20% FY27 guidance. New-brand pipeline (Senator, Polipluz) showing traction would reinforce the bull narrative. A weak quarter: Revenue miss below ₹620 Cr or EBITDA margin sliding below 12.5% would flag that volume growth is being outpaced by cost headwinds, or demand is softer than guidance suggests. Any commentary weakness on new-brand adoption or demand visibility would weigh.
On Track for FY27?
CERA guided for 18–20% FY27 revenue growth and 7–8% sanitaryware volume growth, anchored to improving retail demand and market activity. Q4 FY26 revenue was ₹643.8 Cr; scaling that evenly would put Q1 at or above ₹650 Cr. The real test is whether margins can stabilize as the company laps prior-year input-cost inflation. Q4 EBITDA margin of 15.2% was down 310 basis points yoy—if Q1 shows meaningful recovery toward the 14–15% band management has targeted, it signals disciplined cost management. If margins stay compressed, the Street will question whether the top-line growth is being built on price hikes or genuine volume momentum.
What the Street Says
Since Last Quarter: The CBO Departure & Dividend Tail
On July 21, 2026, Ramesh Baliga, Chief Business Officer of Polymers and Emerging Business India, resigned due to personal reasons. This touches a key growth pillar—new verticals and emerging brands like Senator and Polipluz fall under his remit. Management acceptance of the resignation and smooth handover will be essential messaging on the Aug 8 call. On the positive side: The board approved a ₹75-per-share dividend (1,500% on ₹5 face value) for FY26, with a record date of July 7—this reflects cash generation and shareholder-friendly capital allocation. Routine items: AGM held Jul 23; 2,109 ESOP options exercised; insider trading window closed (opened post-result). FII ownership declined 42 basis points to 14.19% as of Q4 FY26, while DII ownership was stable.
What to Watch on Result Day
1 · Revenue Run-Rate & Volume Mix
Does Q1 revenue land at ₹630–650 Cr (on the ₹643 Cr Q4 base)? Break out core sanitaryware vs. faucetware vs. new brands—volume growth and price realization separately matter.
2 · EBITDA Margin Recovery
Is Q1 EBITDA margin at 14% or above, signaling cost absorption? A slip to <13% would suggest input headwinds are not abating and raise FY27 margin guidance risk.
3 · New Brands (Senator, Polipluz) Progress
Any revenue contribution or ramp detail from new verticals? Management commentary on ₹70–80 Cr target for FY27 and Q1 trajectory will set confidence for the full-year 18–20% growth story.
4 · CBO Transition & Management Narrative
How is management positioning the CBO departure? Is there a clear successor or plan for emerging-business oversight? Smooth handover narrative will matter to offset execution risk in a key growth segment.
CERA trades at a strong momentum going into Q1 FY27 results—up 41% from the 52-week low, pricing in the FY27 18–20% revenue growth and new-brand ramp. The headline will be whether the core business can sustain volume growth on-plan while margins recover from the Q4 compression. Input-cost tailwinds have been scarce; any evidence of pricing power or cost absorption on the Q1 print will be read as execution strength. The CBO departure is a subplot—not a dealbreaker, but a reminder that emerging-vertical execution is a key dependency. Watch the margin trend and new-brand commentary closely.
Growth delivered, margin recovery hinges on execution—not yet proven
Revenue grew 15.1% YoY, but management's 19.5% claim fell short by 4.4 percentage points. The real story: EBITDA margin compressed to 10.1%, well below the 13.5–14% FY27 guidance, and the ₹4.35 crore one-time cost rebound is not yet in the bag.
₹486 Cr
+15.1% YoY (claimed 19.5%)
10.1%
vs 13.1% prior year; −300 bps
₹45.3 Cr
−3.7% YoY (no operating leverage)
On the call, management opened with 19.5% revenue growth. The result delivered 15.1%. That 4.4-percentage-point gap is not a rounding error—it signals either a forecast miss or an accounting adjustment that underestimated headwinds. But the real story is margin. EBITDA compressed to 10.1% from 13.1% a year ago, and sits a full 300+ basis points below the company's 13.5–14% FY27 guidance. Management blames ₹4.35 crore in one-time costs and claims recovery is on track. The market is not convinced yet.
The claim vs. what holds up
Revenues grew 19.5% YoY
Delivered 15.1% YoY (₹486 Cr vs ₹422 Cr prior-year equivalent)
Overstated by 4.4pp
FY27 EBITDA margins to stay at 13.5–14%
Q1 EBITDA margin 10.1% (vs 13.1% prior year); ₹4.35 Cr one-time claimed
Contradicted; margin miss already evident in Q1
Strong operating leverage from revenue growth
PAT declined 3.7% YoY despite 15.1% revenue growth
Contradicted; no leverage visible
One-time costs (₹4.35 Cr / 4.35% of revenue) will not recur beyond Q2
Wage settlement ₹6.3 Cr is prior-period; structural wage cost ₹18.3 Cr FY27 is NOT one-time. Project lag extends into Q2.
Partially supported; wage cost reset structurally higher
Volume-driven growth: Sanitaryware 10%, Faucetware 18%
Supported by segment data: Sanitaryware +14% (10% vol + 2% price + 2% mix); Faucetware +25% (18% vol + 4% price + 3% mix)
Supported
Why the margin miss is the story
Here's the reconciliation: reported Q1 EBITDA was ₹49.1 Cr (10.1% margin). Management claims ₹4.35 Cr in one-time costs—wage backfill ₹6.3 Cr (−1.3%), kiln under-absorption ₹3.7 Cr (−0.75%), project pricing lag ₹4 Cr (−0.8%), and delayed price realization 1.5%. Remove those, and EBITDA would be ~₹70.2 Cr, or 14.5%—right in line with their FY27 guide. The problem: this rebound is not yet proven. Q2 will still carry project pricing lag. Q3 is when new project contracts should convert to revised pricing. And hanging over everything is a structural wage cost increase of ₹18.3 Cr for the full FY27 (₹1 Cr per month run-rate)—that's a 15–20% hike to base wages from the union settlement, and it's here to stay.
If I add all of them, I will find that it is resulting in a kind of one-time impact of 4.35%. The current EBITDA was 10.1%. So effectively, if this one-time impact was not there, my EBITDA would have been in the range of 14.5%.
What changed on this call
Three material shifts from prior guidance: First, wage cost reset. The May 2026 union settlement locked in a 15–20% hike to base wages, effective Sep 2025–Mar 2026 retroactively. That ₹18.3 Cr impact for full-year FY27 is a structural floor to profitability, not a transient swing. Second, greenfield expansion decision pushed. The ₹130–150 Cr capex for a new sanitaryware plant, deferred from mid-2025, is now under review—decision by end-FY27 based on demand trajectory. This signals caution on growth assumptions. Third, new-brand metrics withheld. Senator and Polipluz are described as "young initiatives, difficult to break out quarterly," so no detail on progress toward the ₹70–80 Cr revenue target. This prevents independent assessment of how the newer brands are tracking.
What the market thinks
The stock fell on day 1 (−0.68% post-result to ₹6062 pre-result close), and the decline widened and held: −2.91% by day 3, −3.13% by day 5. This is not a day-1 pop that fades; it's steady selling, and the market is telling you it does not believe the margin recovery story. Current price ₹5872 sits −12.88% below the all-time high and −4.9% below the 50-day moving average (₹6175.61), though it's still +31.63% above the 52-week low. RSI is 32.6, neutral; volume is normal. Ownership tells a similar story: Foreign investors have trimmed from 17.18% a year ago to 15.43% now, though the latest quarter-on-quarter shows a rebound of +1.24pp, suggesting some bargain-hunting at lower levels. Domestic institutions are stable. The bulk deals (Goldman Sachs buying, HDFC selling, both at ₹5480 in early Jun) show no insider-linked activity, just portfolio rebalancing.
The bull-bear ledger
Revenue growth real: 15.1% YoY, volume-driven (10–18% segment volume gains)
Pricing power demonstrated: May price hikes (12% Sanitaryware, 16% Faucetware) absorbed by market without volume loss
Working capital efficiency gained: cash cycle cut 25 days YoY to 50 days
Capacity utilization tight (Faucetware 96%), signaling demand strength for H2 expansion to capture
Reported PAT fell 3.7% YoY despite 15.1% revenue growth—no operating leverage evident
EBITDA margin miss vs. guidance (10.1% vs 13.5–14%) already visible in Q1, not a Q2 surprise
Wage cost ₹18.3 Cr FY27 is structural (union-negotiated, 15–20% hike), not one-time; offsets operational efficiencies
Commodity inflation (brass ₹900/kg, gas ₹48.43/cm³) may persist; gross margin compressed to 46% from 50%+
Project pricing lag extends into Q2; recovery to 13.5–14% contingent on Q3 contract conversion
Risks to watch, ranked by how much they should concern a holder
Margin recovery fails to materialize beyond Q2
HighIf project contracts don't convert to new pricing by Q3, or commodity prices (brass ₹900/kg, gas) stay elevated, Q3 rebound doesn't happen. Full-year EBITDA margin guidance (13.5–14%) at risk. Market has already priced in skepticism.
Brass price escalates beyond ₹950/kg
HighFaucetware is 40% of revenue and highest-margin segment. Brass cost surge (₹665→₹900 Dec–Jul) hit gross margin hardest (46% vs 50%+). Management stated further hikes likely if brass breaches ₹950. Retail pricing lag is 2–3 months; projects are 1 quarter+.
Structural wage cost ₹18.3 Cr floors profitability
HighUnion settlement ₹1 Cr/month run-rate is permanent baseline post-Nov. This is not one-time and offsets operational efficiencies. Without price hikes or volume acceleration, margin floor drops.
Capacity bottleneck if demand accelerates
MediumFaucetware at 96% utilization; brownfield expansion lands Q4 FY27. If demand jumps in Q2–Q3 before capacity comes online, growth caps or outsourcing costs rise.
Demand cycle turns if macro slows
MediumSegment growth (Sanitaryware +14%, Faucetware +25%) is volume-based, not price-driven. Real estate and construction cycles are cyclical. Slowdown compresses the 15–18% volume gains assumed for H2.
Management continuity on new brands
LowCEO of Senator/Polipluz exiting Sep 30; transition to existing national head. Early-stage brands rely on leadership continuity, but process and teams are in place.
The debate
1 · Q2 EBITDA margin and one-time cost recurrence
If margin stays at 10–11% even after removing project lag impact, the structural headwind (wage inflation, commodity pressure) is larger than claimed. Project lag should ease by 5% of the gross margin compression; if it doesn't, recovery is at risk.
2 · Brass price and gross margin trajectory
Management expects gross margin recovery to 51% by Q3 if brass holds at ₹900/kg. If brass breaches ₹950, further price hikes are needed—confirm whether retail/project market will absorb them without volume loss.
3 · Project contract wins and old-price order rundown
Q3 earnings call will show the pace of project pricing conversion. Management guided for ₹4 Cr project closure impact in Q1; Q2 and Q3 conversion rate will confirm whether H2 recovery is on track.
CERA is not broken, but Q1 showed that the company underestimated the headwinds—both the pace of commodity inflation and the timing of cost recovery. Revenue growth is real. Pricing power is real. But margin credibility is dented, and the rebound is contingent on execution, not guaranteed. The stock's −3.13% decline by day 5 and FII trimming suggest the market is adopting a wait-and-see posture. That's the right call. Track Q2 organic EBITDA and Q3 project pricing conversion. If both deliver, the ₹5872 price offers value. If either slips, the 13.5–14% guidance is at risk, and the stock re-rates lower.
Cera Q1 FY27 (standalone): PAT -3% YoY as margins compress to ~10% on 19% revenue growth
PAT -2.63% YoY · revenue +19.46% · margins compressing · miss vs street
₹485.98 Cr
+19.46% YoY
₹45.31 Cr
-2.63% YoY
8.93%
-1.8pp YoY
₹35.13
Cera Sanitaryware's standalone Q1 FY27 (quarter ended June 30, 2026) revenue came in at ₹485.98 Cr, up 19.5% YoY from ₹406.81 Cr a year ago — tracking management's FY27 guidance of 18-20% revenue growth. But profitability moved the other way: PAT was ₹45.31 Cr, down 2.6% YoY from ₹46.53 Cr, as operating margin (OPM) compressed to ~10.1% from ~13.0% a year earlier and net margin fell to ~9.3% from ~11.4%. There were no exceptional items in either the current or year-ago quarter, so the YoY PAT decline is like-for-like — a genuine margin miss, not a base-effect artifact. Against management's own FY27 EBITDA margin band of 14-15% reiterated on the May concall, Q1's ~10.1% OPM is a clear shortfall even as topline growth stayed on script.
Q1 FY-2027 vs prior quarters
The compression sits mainly on the materials and trade-discount lines: cost of materials plus stock-in-trade purchases together outpaced revenue growth, consistent with management's earlier flag that elevated brass input costs and a gradual reduction in trade discounts would need to be offset by recent price hikes — an offset that hasn't shown up yet in this quarter's numbers. Sequentially, revenue fell 22.1% and PAT fell 41.4% QoQ from the seasonally strong Q4 FY26 (₹624.00 Cr revenue, ₹77.34 Cr PAT); that drop is largely the normal Q4-to-Q1 seasonal step-down for the building-products sector rather than fresh deterioration, so YoY remains the read that matters. Against our pre-result preview, which had penciled in Q1 revenue of ~₹633 Cr and an EBITDA margin of 13-14% (anchored close to Q4's run-rate without fully discounting seasonality), the actual print undershoots meaningfully on both counts; EPS of ₹35.13 also missed the ~₹53.1 forward estimate. The Street's pre-result debate — whether new brands scale sustainably or input-cost volatility keeps clipping margins — resolved toward the latter this quarter.
The stock went into the print at ₹6,069, down 3.5% over the past month of trading.
What the summary numbers don't show
No exceptional items this quarter, unlike the ₹18.46 Cr labour-code provision in Q3 FY26 and its ₹10.65 Cr reversal in Q4 FY26
Management guides for robust 18-20% revenue growth in FY27, driven by strong volume and price increases in the core faucetware (18% growth) and sanitaryware (12% growth) segments. They expect to sustain EBITDA margins in the 14-15% range by offsetting elevated input costs through recent price hikes and a gradual reduct
— This quarter: missed
Two quarter developments carry into the read: the CBO resigned on July 21, 2026, just ahead of this print and the August 8 earnings call, adding an execution-narrative question on top of the margin miss; and the board's ₹75/share FY26 dividend was ratified at the July 23 AGM, unrelated to the operating print. Management issued no fresh guidance in this filing — the standing 18-20% revenue growth and 14-15% margin targets from the May concall remain in force — leaving the August 8 call as the next checkpoint for whether pricing actions can close the margin gap.
W1
Margin recovery path toward the guided 14-15% FY27 EBITDA band from Q1's ~10.1% OPM — first test at the Aug 8 concall
W2
New brands Senator and Polipluz progress toward the ₹70-80 Cr combined revenue target
W3
CBO transition and management narrative on execution continuity post-resignation
Only one statement is presented in this filing (no separate consolidated section). No exceptional items in the current or year-ago quarter — the exceptional items visible in the table (₹18.46 Cr labour-code provision in Q3 FY26, ₹10.65 Cr reversal in Q4 FY26) fall in the other comparative columns and don't affect this YoY comparison.